Research Facilities and Resources
Retroviral and adenoviral vectors, as well as non-viral vector systems, have been merged into one of the most powerful approaches in understanding basic physiological and pathological roles of normal, mutated or deficient genes. The Viral Vector Laboratory produces recombinant viral vectors for gene transfer into mammalian cells, gene delivery and gene therapy. This Biosafety Level-3 facility which occupies approximately 1,000 sq. ft. in the Department of Pharmacology, is built according to GIVIP standards and has its own self-contained air-flow system.
Researchers interested in developing and using gene transfer collaborate with vector construction specialists to design and develop gene constructs, assess their functionality and produce sufficient material for experimentation. In addition, viral vectors for human gene therapy are designed, developed and examined for function and efficacy. Examples include genes that modulate the immune system and prevent the rejection of organ transplants. Vector development for gene therapy against prostate and breast cancer are also underway.
Ongoing projects in the Viral Vector Laboratory focus on the development of viral vectors to treat leukemia and cardiovascular diseases. A retrovirus vector containing the interferon alpha gene, which has been constructed for treatment of leukemia, is being tested in human cell lines and bone marrow to assess its efficacy. Adenovirus- and retrovirus-constructs overexpressing cyclooxygenase, prostacycline synthase and heme oxygenase are being developed to assess their potential in preventing arterial thrombosis.
Contact:Nader G. Abraham, Ph.D.
Director, Gene Therapy Program
New York Medical College
Department of Pharmacology
Basic Sciences Building
Valhalla, NY 10595
Tel: 914/594-4132
Fax: 914/347-4956
E-Mail: nader_abraham@nymc.edu
